9.23
18.56 (02.01%)
As of Mar 06, 2024
BAUSCH HEALTH COMPANIES INC. [BHC]
As of Feb 22, 2024 | Source: Annual Report to the SEC
Company Overview
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter products and aesthetic medical devices.
| Country | United States |
| Phone Number | 514-744-6792 |
| Industry | Chemicals And Allied Products |
| Employees | 20,270 |
| CEO | Thomas J. Appio |
| Website | www.bauschhealth.com |
Bausch Health Companies Inc. [BHC] As of Nov 03, 2022| Source: Quarterly Report to the SEC Bausch Health Companies Inc. is a global company whose mission is to improve peoples lives with our health ca...
Valeant Pharmaceuticals International, Inc. [BHC] As of Nov 07, 2017| Source: Quarterly Report to the SEC Bausch Health Companies Inc. is a global company whose mission is to improve peoples lives wit...
Valeant Pharmaceuticals International, Inc. [BHC] As of May 09, 2017| Source: Quarterly Report to the SEC Bausch Health Companies Inc. is a global company whose mission is to improve peoples lives wit...
Valeant Pharmaceuticals International, Inc. [BHC] As of Aug 08, 2017| Source: Quarterly Report to the SEC Bausch Health Companies Inc. is a global company whose mission is to improve peoples lives wit...
Bausch Health Companies Inc. [BHC] As of May 10, 2022| Source: Quarterly Report to the SEC Bausch Health Companies Inc. is a global company whose mission is to improve people’s lives with our health c...
Financial Overview
| Revenue | 8,757 M |
| Operating Revenue | 963 M |
| Profits | -611 M |
| Net Cash | 371 M |
Management Effectiveness
| Return on Equity | 745.12% |
| Return on Assets | -2.23% |
| Turnover Ratio | 0.33 M |
| EBITDA | 2,040 M |
Profit Ratios
| Operating Margin | 11% |
| Profit as % of Assets | -2.3% |
| Profit as % of Stockholder Equity | 745.12% |
Balance Sheet and Cash Flow Measures
| Total Assets | 27,350 M |
| Total Liabilities | 27,432 M |
| Operating Cash Flow | 1,032 M |
| Investing Cash Flow | -2,145 M |
| Financing Cash Flow | 1,475 M |